GMT Capital Corp Purchases 164,100 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• GMT Capital Corp has increased its holdings in Jazz Pharmaceuticals by 32.3% during the first quarter, now owning 672,900 shares, which represents 4.4% of its portfolio.
• Jazz Pharmaceuticals reported a loss of ($8.25) earnings per share for the last quarter, missing analysts' estimates, even as revenue grew by 2.1% year-over-year.
• Institutional investors and hedge funds own 89.14% of Jazz Pharmaceuticals, indicating strong institutional interest in the company.

GMT Capital Corp boosted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 32.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 672,900 shares of the specialty pharmaceutical company's stock after purchasing an additional 164,100 shares during the quarter. Jazz Pharmaceuticals comprises 4.4% of GMT Capital Corp's holdings, making the stock its 9th biggest position. GMT Capital Corp owned 1.09% of Jazz Pharmaceuticals worth $83,541,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Focus Partners Wealth acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth about $551,000. CX Institutional acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $4,316,000. Envestnet Portfolio Solutions Inc. grew its position in shares of Jazz Pharmaceuticals by 38.9% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company's stock valued at $542,000 after purchasing an additional 1,223 shares during the period. GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 63.7% in the 1st quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock valued at $126,000 after purchasing an additional 395 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $1,888,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Up 1.6%

Shares of Jazz Pharmaceuticals stock traded up $2.06 on Wednesday, reaching $131.72. 652,066 shares of the company were exchanged, compared to its average volume of 947,196. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The company has a market capitalization of $7.99 billion, a price-to-earnings ratio of -19.57, a PEG ratio of 8.04 and a beta of 0.24. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company has a 50-day moving average of $115.33 and a 200 day moving average of $117.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the company earned $5.30 EPS. The company's revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the sale, the chief executive officer owned 436,973 shares in the company, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JAZZ. Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Piper Sandler reiterated an "overweight" rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Robert W. Baird cut their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price on the stock. Fourteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $178.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.